Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
FIVE9
FIVN
$2.53B
| $17.5M | 0.01% |
266,900
-278,900
| -51% | -$17.1M |
|
1077
AMERISAFE
AMSF
$517M
| $17.4M | 0.01% |
263,893
+800
| +0.3% | +$53K |
|
|
CGC
1078
Canopy Growth
CGC
$426M
| $17.4M | 0.01% |
82,770
+31,680
| +62% | +$6.29M |
|
1079
Tompkins Financial
TMP
$1.44B
| $17.4M | 0.01% |
189,892
-25,930
| -12% | -$2.24M |
|
1080
Voyager Therapeutics
VYGR
$197M
| $17.4M | 0.01% |
1,245,501
+172,600
| +16% | +$2.51M |
|
1081
Pebblebrook Hotel Trust
PEB
$2.04B
| $17.4M | 0.01% |
647,595
+378,695
| +141% | +$9.98M |
|
1082
FTI Consulting
FCN
$4.24B
| $17.4M | 0.01% |
156,800
+14,000
| +10% | +$1.53M |
|
|
PFNX
1083
DELISTED
Pfenex Inc.
PFNX
| $17.3M | 0.01% |
1,579,805
+56,000
| +4% | +$556K |
|
|
HCCI
1084
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
| $17.3M | 0.01% |
551,300
+133
| +0% | +$3.81K |
|
|
SAND
1085
DELISTED
Sandstorm Gold
SAND
| $17.3M | 0.01% |
2,317,610
+33,910
| +1% | +$221K |
|
1086
Hanmi Financial
HAFC
$956M
| $17.2M | 0.01% |
862,657
-46,100
| -5% | -$890K |
|
|
RARX
1087
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $17.2M | 0.01% |
+366,845
| New | +$16.2M |
|
1088
S&P Global
SPGI
$125B
| $17.2M | 0.01% |
+62,900
| New | +$16.3M |
|
1089
Macerich
MAC
$6.99B
| $17.2M | 0.01% |
637,419
+332,269
| +109% | +$9.13M |
|
1090
CytomX Therapeutics
CTMX
$760M
| $17.1M | 0.01% |
2,063,271
+530,971
| +35% | +$3.58M |
|
1091
BioMarin Pharmaceuticals
BMRN
$13.6B
| $17.1M | 0.01% |
202,471
-353,600
| -64% | -$26.7M |
|
1092
J.M. Smucker
SJM
$12.7B
| $17.1M | 0.01% |
164,403
-164,077
| -50% | -$17.4M |
|
|
CLR
1093
DELISTED
CONTINENTAL RESOURCES INC.
CLR
| $17.1M | 0.01% |
498,300
-195,500
| -28% | -$6.07M |
|
1094
Orthofix Medical
OFIX
$415M
| $17.1M | 0.01% |
369,269
-48,421
| -12% | -$2.28M |
|
1095
Western New England Bancorp
WNEB
$282M
| $17M | 0.01% |
1,768,089
+27,462
| +2% | +$265K |
|
|
THR
1096
DELISTED
Thermon Group Holdings
THR
| $17M | 0.01% |
633,900
-10,200
| -2% | -$257K |
|
|
SPNS
1097
DELISTED
Sapiens International
SPNS
| $16.9M | 0.01% |
736,900
+96,500
| +15% | +$2.09M |
|
1098
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.5B
| $16.8M | 0.01% |
268,400
+197,800
| +280% | +$12M |
|
|
HABT
1099
DELISTED
The Habit Restaurants, Inc. - Class A
HABT
| $16.8M | 0.01% |
1,613,700
-22,800
| -1% | -$227K |
|
|
FLG
1100
Flagstar Bank National Association
FLG
$5.9B
| $16.8M | 0.01% |
466,708
-766,767
| -62% | -$28.3M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.